Skip to Content

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days 

Late-breaking data from EHA 2022 present phase 2 results from the first multi-center randomized trial comparing two chemotherapy regimens in Burkitt lymphoma (BL). 

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top